Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events

被引:123
作者
Bowry, Ashna D. K.
Brookhart, M. Alan
Choudhry, Niteesh K.
机构
[1] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
D O I
10.1016/j.amjcard.2007.11.057
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antiplatelet agents are central to the treatment and prevention of cardiovascular disease. Although aspirin is the most widely used agent, randomized trials have assessed whether adding clopidogrel to aspirin ("dual-antiplatelet therapy") offers additional benefit with acceptable safety. Unfortunately, these trials have reached conflicting results, in part because of the heterogenous populations they studied. To clarify the role of dual-antiplatelet therapy for patients with vascular disease, a systematic review and metaanalysis of randomized controlled trials was performed. Medline and the Cochrane Collaboration and American College of Physicians Journal Club databases were searched for trials published from 1966 to August 2006 that compared aspirin and clopidogrel with antiplatelet monotherapy. Only trials that presented clinically relevant efficacy and safety outcomes were included. From each trial, demographic data and outcomes were recorded. Summary odds ratios and 95% confidence intervals (Cls) were calculated using a random-effects model. Eight trials comprising 91,744 patients were included. Mean follow-up ranged from 28 days to 18 months. Compared with aspirin alone, dual therapy with aspirin and clopidogrel reduced the odds ratio of the composite outcome of death, reinfarction, and stroke by 15% (95% CI 23% to 6%) in patients with acute coronary syndromes and by 34% (95% Cl 44% to 22%) in patients who underwent percutaneous coronary intervention. Dual therapy also significantly reduced the odds of fatal and nonfatal reinfarction in these patient groups but did not significantly reduce the odds of all-cause mortality. Dual therapy was associated with significantly increased risk for major bleeding in studies > I month in duration (odds ratio 1.80, 95% CI 1.40 to 2.30). In conclusion, combining aspirin and clopidogrel significantly reduces the odds of major cardiovascular events in patients with acute coronary syndromes or those who undergo percutaneous coronary intervention but at the expense of significant increases in the risk for bleeding. (C) 2008 Elsevier Inc.
引用
收藏
页码:960 / 966
页数:7
相关论文
共 21 条
[1]   Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial [J].
Bhatt, Deepak L. ;
Flather, Marcus D. ;
Hacke, Werner ;
Berger, Peter B. ;
Black, Henry R. ;
Boden, William E. ;
Cacoub, Patrice ;
Cohen, Eric A. ;
Creager, Mark A. ;
Easton, J. Donald ;
Hamm, Christian W. ;
Hankey, Graeme J. ;
Johnston, S. Claiborne ;
Mak, Koon-Hou ;
Mas, Jean-Louis ;
Montalescot, Gilles ;
Pearson, Thomas A. ;
Steg, P. Gabriel ;
Steinhubl, Steven R. ;
Weber, Michael A. ;
Fabry-Ribaudo, Liz ;
Hu, Tingfei ;
Topol, Eric J. ;
Fox, A. A. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (19) :1982-1988
[2]   Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [J].
Bhatt, DL ;
Fox, KAA ;
Hacke, W ;
Berger, PB ;
Black, HR ;
Boden, WE ;
Cacoub, P ;
Cohen, EA ;
Creager, MA ;
Easton, JD ;
Flather, MD ;
Haffner, SM ;
Hamm, CW ;
Hankey, GJ ;
Johnston, SC ;
Mak, KH ;
Mas, JL ;
Montalescot, G ;
Pearson, TA ;
Steg, PG ;
Steinhubl, SR ;
Weber, MA ;
Brennan, DM ;
Fabry-Ribaudo, L ;
Booth, J ;
Topol, EJ ;
Frye, RL ;
Amarenco, P ;
Brass, LM ;
Buyse, M ;
Cohen, LS ;
DeMets, DL ;
Fuster, V ;
Hart, RG ;
Marler, JR ;
McCarthy, C ;
Schoemig, A ;
Lincoff, AM ;
Brener, SJ ;
Sila, CA ;
Albuquerque, A ;
Aroutiounov, G ;
Artemiev, D ;
Atkeson, BG ;
Bartel, T ;
Basart, DCG ;
Lima, AB ;
Belli, G ;
Bordalo e Sa, AL ;
Bosch, X .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1706-1717
[3]   ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) [J].
Braunwald, E ;
Antman, EM ;
Beasley, JW ;
Califf, RM ;
Cheitlin, MD ;
Hochman, JS ;
Jones, RH ;
Kereiakes, D ;
Kupersmith, J ;
Levin, TN ;
Pepine, CJ ;
Schaeffer, JW ;
Smith, EE ;
Steward, DE ;
Theroux, P ;
Gibbons, RJ ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Hiratzka, LF ;
Jacobs, AK ;
Smith, SC .
CIRCULATION, 2002, 106 (14) :1893-1900
[4]   Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial [J].
Chen, ZM ;
Jiang, LX ;
Chen, YP ;
Xie, JX ;
Pan, HC ;
Peto, R ;
Collins, R ;
Liu, LS ;
Chen, ZM ;
Liu, LS ;
Collins, R ;
Jiang, LX ;
Chen, YP ;
Xie, JX ;
Pan, HC ;
Peto, R ;
Cai, NS ;
Chen, YZ ;
Cui, JJ ;
Dai, GZ ;
Feng, JZ ;
Fu, SY ;
Gent, M ;
Gong, LS ;
Hu, DY ;
Huang, DJ ;
Huang, J ;
Huang, TG ;
Huang, ZW ;
Hui, RT ;
Jiang, BQ ;
Li, DY ;
Li, SM ;
Li, TD ;
Li, YQ ;
Li, ZQ ;
Liu, YH ;
Meng, QY ;
Qian, TJ ;
San, J ;
Tao, SQ ;
Wang, DW ;
Wang, LH ;
Wang, W ;
Wu, HA ;
Xi, WH ;
Xu, CB ;
Yang, DC ;
Yang, XF ;
Yin, JQ .
LANCET, 2005, 366 (9497) :1607-1621
[5]   Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial [J].
Diener, HC ;
Bogousslavsky, J ;
Brass, LM ;
Cimminiello, C ;
Csiba, L ;
Kaste, M ;
Leys, D ;
Matias-Guiv, J ;
Rupprecht, HJ .
LANCET, 2004, 364 (9431) :331-337
[6]   Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation [J].
Eisenstein, Eric L. ;
Anstrom, Kevin J. ;
Kong, David F. ;
Shaw, Linda K. ;
Tuttle, Robert H. ;
Mark, Daniel B. ;
Kramer, Judith M. ;
Harrington, Robert A. ;
Matchar, David B. ;
Kandzari, David E. ;
Peterson, Eric D. ;
Schulman, Kevin A. ;
Califf, Robert M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (02) :159-168
[7]   Role of clopidogrel in managing atherothrombotic cardiovascular disease [J].
Eshaghian, Shervin ;
Kaul, Sanjay ;
Amin, Sameer ;
Shah, Prediman K. ;
Diamond, George A. .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (06) :434-441
[8]   Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. [J].
Gaspoz, J ;
Coxson, PG ;
Goldman, PA ;
Williams, LW ;
Kuntz, KM ;
Hunink, MGM ;
Goldman, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (23) :1800-1806
[9]   A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [J].
Gent, M ;
Beaumont, D ;
Blanchard, J ;
Bousser, MG ;
Coffman, J ;
Easton, JD ;
Hampton, JR ;
Harker, LA ;
Janzon, L ;
Kusmierek, JJE ;
Panak, E ;
Roberts, RS ;
Shannon, JS ;
Sicurella, J ;
Tognoni, G ;
Topol, EJ ;
Verstraete, M ;
Warlow, C .
LANCET, 1996, 348 (9038) :1329-1339
[10]   Assessing the quality of reports of randomized clinical trials: Is blinding necessary? [J].
Jadad, AR ;
Moore, RA ;
Carroll, D ;
Jenkinson, C ;
Reynolds, DJM ;
Gavaghan, DJ ;
McQuay, HJ .
CONTROLLED CLINICAL TRIALS, 1996, 17 (01) :1-12